warning_amberWhat You Should Know

Compounded vs Brand-Name GLP-1

A side-by-side comparison of compounded and FDA-approved GLP-1 medications — what each is, how they differ, and what changed in late 2024.

For roughly two years, compounded semaglutide and tirzepatide were a meaningful slice of the U.S. GLP-1 market. They were cheaper, often easier to access through telehealth, and legally available because both drugs were on the FDA's shortage list. As of 2026, that picture has changed — the shortages were declared resolved, and the legal protections for compounded versions have largely ended.

This guide isn't a recommendation in either direction. It's a side-by-side look at how compounded and brand-name GLP-1s actually differ on the things that matter: regulation, identity, dosing format, cost, and access. Where the trade-offs are real, we name them.

The legal and pricing landscape continues to shift. Assume dates and prices in this article are accurate as of 2026 and verify with the manufacturer or pharmacy before deciding.

What "brand-name" and "compounded" actually mean

A brand-name GLP-1 — Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza — is an FDA-approved finished product manufactured by a pharmaceutical company (Novo Nordisk or Eli Lilly for these). The FDA has reviewed clinical trial data, manufacturing processes, labeling, and post-market safety reports. The product is shipped in a pre-filled pen or vial with a specific dose, specific inactive ingredients, and documented stability data.

A compounded GLP-1 is prepared by a compounding pharmacy rather than a manufacturer. Compounding pharmacies fall into two categories. 503A pharmacies are state-licensed traditional compounders that prepare patient-specific prescriptions. 503B outsourcing facilities are federally registered and operate under stricter quality standards but still without an FDA-approved finished product. Compounded GLP-1s typically arrived as a multi-dose vial with a separate syringe, often with a salt form (semaglutide sodium, tirzepatide acetate) that differs from the brand product.

The big practical difference: brand-name products are FDA-tested for identity, potency, sterility, and stability. Compounded products are not. The FDA monitors compounding pharmacies for general operating standards, but it does not test every batch of every compounded product.

Where things stand in 2026

The FDA listed semaglutide as in shortage in August 2022 and tirzepatide in December 2022. Under federal compounding law, that listing was the legal hook that allowed compounding pharmacies to prepare these drugs at scale.

Both shortages were declared resolved in late 2024 — tirzepatide first (October 2024, finalized in December), then semaglutide (formally resolved in October 2024 with a similar transition pattern). After short transition windows, 503A and 503B pharmacies were generally expected to stop preparing these drugs for routine use. As of 2026, broad commercial compounding of semaglutide and tirzepatide has largely ended.

Several telehealth platforms that depended on compounded GLP-1s have transitioned patients onto manufacturer self-pay programs — Novo Nordisk's NovoCare Pharmacy for Wegovy (around $349/month) and Eli Lilly's LillyDirect for Zepbound vials ($299–$449/month depending on dose).

How they compare on the things that matter

Regulatory status. Brand-name GLP-1s are FDA-approved drugs. Compounded GLP-1s are not approved as finished products; they are prepared per prescription under compounding-pharmacy rules, with no FDA review of safety or efficacy.

Active ingredient. Brand products use one specific molecular form of semaglutide or tirzepatide. Compounded products have used several forms — including semaglutide sodium and semaglutide acetate, which the FDA explicitly noted have not been shown safe or effective in humans.

Inactive ingredients. Brand-name products have a fixed list of excipients (buffers, preservatives, stabilizers) disclosed on the label. Compounded products vary by pharmacy and batch. Some patients with documented sensitivities to brand excipients sought compounded for that reason; others ended up reacting to compounded excipients instead.

Dosing format. Brand-name GLP-1s come in pre-filled pens with click-based dose marks (or, for Zepbound, also in single-dose vials through LillyDirect). Compounded versions are typically multi-dose vials with a separate syringe. The vial-and-syringe format is where most reported dosing errors happen.

Cost. Brand-name retail pricing without insurance is roughly $1,300–$1,500 per month. With commercial insurance plus a manufacturer savings card, monthly out-of-pocket can drop to $25–$100. Manufacturer self-pay programs are $299–$449/month for Zepbound vials and around $349/month for Wegovy. Compounded versions during the shortage were often $150–$300/month before the legal cover ended.

Access. Brand products are dispensed through pharmacies (retail or manufacturer-direct) with a standard prescription. Compounded products historically came through telehealth platforms that paired a prescriber with a partner compounding pharmacy. With the shortage resolved, those channels for routine GLP-1 compounding have closed.

What to watch for

warning

Dosing errors

Pre-filled pens largely prevent dose miscounts. Multi-dose vials with syringes — the compounded format — are where 10x overdoses keep happening. If you ever switch between formats, get a written draw chart from a pharmacist.

biotech

Identity and potency

Brand products are tested by the manufacturer and FDA for identity, potency, and content uniformity. Compounded products are not FDA-tested. If you're using a compounded product, the salt form and actual peptide content can vary from pharmacy to pharmacy.

verified_user

Pharmacy verification

For any compounded prescription, look up the pharmacy with your state board, check FDA warning letters, and ask in writing about API source and testing. For brand-name products, verify the pharmacy is a legitimate licensed pharmacy — not an unlicensed website selling 'research peptides.'

Common questions

Common Concerns

Is compounded GLP-1 still legal in 2026?expand_more

Broad commercial compounding of semaglutide and tirzepatide for routine weight management is no longer legally protected the way it was during the shortage. Patient-specific compounding for documented clinical needs (such as an allergy to an inactive ingredient in the FDA-approved product) may still happen case-by-case, depending on the state and current FDA enforcement priorities. Rules continue to evolve.

How does the cost actually compare now?expand_more

Brand retail without insurance is roughly $1,300–$1,500/month. Manufacturer self-pay is $299–$449/month for Zepbound vials and around $349/month for Wegovy. Commercial insurance with a savings card brings copays as low as $25/month. Compounded prices in 2023 were often $150–$300/month, but with the legal cover gone, the comparison now is mostly between brand options.

Can I switch from compounded back to a brand-name product?expand_more

Yes. Get a prescription for Wegovy, Ozempic, Zepbound, or Mounjaro from your prescriber. Dose conversion isn't always one-to-one — compounded doses were often customized — so your provider may restart titration or hold you at a similar weekly milligram dose. The manufacturer self-pay programs (NovoCare, LillyDirect) handle the prescription channel for cash-pay patients.

Did compounded versions work as well as brand-name?expand_more

There is no peer-reviewed head-to-head clinical trial comparing compounded and brand-name GLP-1s. Many patients reported similar weight loss on compounded products. Many also reported variability between batches — some doses felt much stronger or weaker. Without standardized potency testing, individual experiences can't be generalized.

Is buying 'research peptide' semaglutide a legal alternative?expand_more

No. Products marketed as 'research peptides' or 'not for human use' are not regulated as drugs and are not legal for personal use. They are not tested for sterility or identity. The FDA has issued multiple warnings about purchasing peptides from these channels. This is meaningfully riskier than a licensed compounding pharmacy was during the shortage.

Keep exploring

Browse all dosing guides.